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MAJOR ARTICLE

Acute Symptoms of Mild to Moderate COVID-19 Are
Highly Heterogeneous Across Individuals and Over Time
1
Department of Psychological and Brain Sciences, Washington University in St Louis, St Louis, Missouri, USA, 2Department of Psychiatry, Washington University School of Medicine (WUSM),
St Louis, Missouri, USA, 3Department of Anesthesiology, WUSM, St Louis, Missouri, USA, 4Institute for Informatics, Division of Biostatistics, WUSM, St Louis, Missouri, USA, 5Department of
Otolaryngology, WUSM, St Louis, Missouri, USA, and 6Department of Internal Medicine, Division of Infectious Diseases, WUSM, St Louis, Missouri, USA

Background. The symptoms of coronavirus disease 2019 (COVID-19) appear to be heterogenous, and the typical course of
these symptoms is unknown. Our objectives were to characterize the common trajectories of COVID-19 symptoms and to assess
how symptom course predicts other symptom changes as well as clinical deterioration.
Methods. One hundred sixty-two participants with acute COVID-19 responded to surveys up to 31 times for up to 17 days.
Several statistical methods were used to characterize the temporal dynamics of these symptoms. Because 9 participants showed clinical deterioration, we explored whether these participants showed any differences in symptom profiles.
Results. Trajectories varied greatly between individuals, with many having persistently severe symptoms or developing new
symptoms several days after being diagnosed. A typical trajectory was for a symptom to improve at a decremental rate, with most
symptoms still persisting to some degree at the end of the reporting period. The pattern of symptoms over time suggested a fluctuating
course for many patients. Participants who showed clinical deterioration were more likely to present with higher reports of severity
of cough and diarrhea.
Conclusions. The course of symptoms during the initial weeks of COVID-19 is highly heterogeneous and is neither predictable nor easily characterized using typical survey methods. This has implications for clinical care and early-treatment clinical trials.
Additional research is needed to determine whether the decelerating improvement pattern seen in our data is related to the phenomenon of patients reporting long-term symptoms and whether higher symptoms of diarrhea in early illness presages deterioration.
Keywords. cough; COVID-19; humans; severe acute respiratory syndrome coronavirus 2; smell; taste.
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Graphical abstract

COVID-19 symptoms generally recede, but symptom courses are
highly heterogenous
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INTRODUCTION

The World Health Organization (WHO) and the Centers
for Disease Control and Prevention (CDC) have described
common symptoms of the coronavirus disease 2019 (COVID19), including fever, dry cough, and difficulty breathing [1, 2].
They also report that many people may have few or no symptoms despite infection. This characterization is based on studies
that report cross-sectional or retrospective accounts of symptoms from chart review or patient interviews [3–10].
Thus, the temporal dynamics of COVID-19 symptoms are
unclear. For example, in a patient currently experiencing fever,
should the patient be concerned about more severe illness if the
fever seems to resolve but returns a day later? Notably, a recent
review of long-term COVID-19 symptoms revealed that some
patients expected a gradual, linear recovery and were troubled
2 • ofid • Rodebaugh et al
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by symptoms that instead waxed and waned [11]. Moreover, if
COVID-19 symptoms have highly heterogeneous trajectories,
this could be a barrier to measuring symptoms as a treatment
outcome, in that reduction in symptoms on average could mask
increases in specific symptoms, such that some patients could
appear to improve (reduction in symptoms overall) while actually deteriorating (eg, increase in shortness of breath alone).
The aim of the current study is to characterize the temporal
dynamics of COVID-19 symptoms in a sample of participants
in a randomized controlled trial testing the medication fluvoxamine (vs placebo) for early COVID-19 treatment [12].
Participants reported on their experience of common COVID19 symptoms, as well as blood oxygen level and other clinical
signs, twice daily for a maximum of 31 times over the course of
a maximum of 17 days.
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Symptom

METHODS
Study Population

Participants were adults living in the community with severe
acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection confirmed by polymerase chain reaction assay who
were currently symptomatic with symptom onset <7 days before beginning survey responses. Exclusion criteria included
COVID-19 severe enough to require hospitalization or meeting
the study’s primary end point for clinical deterioration at
baseline (ie, oxygen saturation of <92% on room air), medical comorbidities including severe underlying lung disease
(chronic obstructive pulmonary disease or home oxygen, interstitial lung disease, pulmonary hypertension), decompensated cirrhosis, congestive heart failure (stage 3 or 4), and being
immunocompromised (solid organ transplant, bone marrow
transplant recipient, AIDS, on biological immunologic medications or high-dose steroids [>20 mg of prednisone per day]).
The clinical trial’s primary outcome measure was clinical
deterioration, defined by meeting both of the following: (1)
presence of dyspnea (ie, shortness of breath) and/or hospitalization for shortness of breath or pneumonia plus (2) decrease
in oxygen saturation (<92%) on room air and/or supplemental oxygen requirement in order to keep oxygen saturation
≥92%. Participants typically stopped completing surveys on
their symptoms once they met the primary outcome criteria.
However, data are available from 1 participant who experienced
moderate deterioration halfway through the trial and continued
to provide data after deterioration. Notably, because we included all participants who provided any symptom survey data,
we report on an additional 10 participants not included in the
parent study [12]; these subjects were excluded from the parent

study because they either could not be confirmed to have taken
the study drug (n = 7) or were deteriorated at baseline (n = 3).
Patient Consent Statement

The study was approved by Washington University’s Institutional
Review Board before initiating any recruitment, and all participants provided informed consent via an e-consent or written
consent.
Survey

Data collection occurred via REDCap surveys sent to participants via email, with telephone-based data collection as a
backup to ensure that individuals without internet access were
able to participate. The data collection used an ecological momentary assessment (EMA) framework. EMA (vs standard data
collection methods) is thought to limit biased responding in
participants due to retrospection because in EMA participants
are asked about their current experience [16]. The surveys recorded COVID-19 symptoms, oxygen saturation, vital signs,
and medication adherence. Participants completed a baseline
survey before starting the study medication, followed by surveys
approximately twice a day for 15 days after starting the study
drug; occasional delayed responding or technical errors led to
a maximum of 17 days. At each survey, participants were asked
whether they were experiencing a symptom at all. When they indicated “no,” this was coded as a value of 0. When they reported
“yes,” they were then asked to rate the perceived severity of the
symptom on a scale from 1 to 10. The symptoms rated included
perceived fever, cough, shortness of breath, fatigue or weakness,
chills, nausea, body aches, diarrhea, loss of appetite, difficulty
with sense of smell, and difficulty with sense of taste.
Statistical Analysis

Analyses were conducted in Mplus [17], with visualizations
produced in R. Because these analyses were not preregistered,
we recommend considering them primarily descriptive and exploratory. Results are reported for the entire group of participants without reference to randomized controlled trial (RCT)
group because there were no clear differences between groups
on latent trajectory outcomes (the same 30 tests were conducted
as reported below for demographic variables, yet the lowest P
value was .015, whereas we considered .01 significant due to the
large number of tests). Additional details on analyses and relevant statistical output are available in the Supplementary Data
as well as at https://osf.io/t8frj/.
RESULTS
Participant Characteristics

In total 162 participants completed at least some EMA surveys (n = 162; median surveys answered, 23; median days covered, 16); demographic data are missing for 10. Participants who
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We used these frequently sampled data to model trajectories
of the self-reported symptoms. That is, we characterized the
course of symptoms using latent trajectory models (also called
latent growth curve models). These models test how to best
characterize the changes in self-reported symptoms across the
course of the study in those participants who ever reported that
symptom. These models are commonly used to study the development of symptoms over time [13, 14].
To model trajectories meaningfully, it is essential to obtain sequential data in real time, without reliance on retrospection.
Asking people to recall events results in poor quality data even
about events that seem highly memorable [15]. With frequently
sampled data over time, a variety of statistical methods allows the
researcher to characterize what is generally true in the sample over
time, as well as to what extent participants vary from this average
trajectory. Thus, we can determine the ways in which symptoms
change over time, as well as whether changes in some symptoms
tend to go together, as might be expected due to some symptoms
being functionally related (eg, problems with smell and taste).

Symptom Frequency and Severity Across and Within Patients Over Time

The most common rating for all symptoms was 0, or not present
(Supplementary Table 1; Supplementary Figure 1). Figure 1,
which depicts raw data for all symptoms for a random set of
participants, demonstrates that the frequent ratings of 0 occurred in a number of patterns, including symptoms never
occurring, occurring and then resolving, starting in the middle
of the reporting period, and fluctuating during some portion of
the reporting period. The frequent “saw tooth” patterns seen in
Figure 1 suggest symptoms waxing and waning. An expanded
version of this figure is available in the Supplementary Figure 2.
Heterogeneity of Symptom Trajectories

To handle the frequent instance of 0s in the data, before proceeding with further analysis we (1) restricted further analysis
to participants who ever had that symptom and (2) consolidated
symptom reports to 5 time points (Times 0 through 4). This
procedure had the effect of “smoothing out” the sawtooth pattern present for many participants, allowing analysis of overall
tendencies over time.
We examined typical trajectories using latent trajectory modeling. These models focus on slopes and intercepts as a way to
characterize the course of symptoms across the whole sample.
The intercept refers to the participant’s estimated level of the
symptom at Time 0 (ie, during the first 3 days of the study). For
participants with only random fluctuations or a stable level of a
Table 1.

Summary of Latent Trajectory Models
Participants in
Analysis

Intercept Mean
(Variance)

Linear Slope Mean
(Variance)

Quadratic Slope Mean
(Variance)

Ache2

120

3.80** (6.45**)

–1.50** (2.10*)

0.20** (0.07*)

Appetite1

121

3.85** (4.45**)

–1.54** (0.99*)

0.18** (0.04*)

Symptom

2

**

**

Breath

89

2.11

(2.86 )

–0.37* (1.33*)

Chill1

74

2.25** (3.63*)

–1.13** (1.54*)

Cough3

129

2.86** (4.65**)

–0.51** (0.94*)

Diarrhea2

100

1.66** (1.68*)

–0.66* (0.00a)

0.08* (0.01)

Fatigue3

144

4.26** (5.34**)

–1.35** (1.61**)

0.15** (0.06**)

3

Fever

72

**

2.26

**

**

(6.06 )

1

**

Smell

112

5.80

Taste3

119

5.06** (9.20**)

(5.79 )

**

(2.84 )

**

(4.20*)

–1.15

–1.32

**

–1.05* (10.67**)

Cubic Slope Mean
(Variance)

0.02 (0.06*)
0.15** (0.04)
0.01 (0.05*)

0.16** (0.08*)
0.10 (0.16*)
–0.07 (1.89**)

0.03 (0.04**)

Latent trajectory models were conducted on participants (n = 162) who ever reported the symptom. The intercept, linear, and quadratic slopes are then given. Intercepts indicate where
participants start, on average, whereas linear slope indicates the general tendency up or down. Additional slopes indicate the extent to which symptom courses frequently reversed, slowed,
or accelerated. Unstandardized estimates are given because these are directly relevant to the response scale of 0 (not at all) to 10 (most severe). Statistically significant slopes indicate
that participants showed a group tendency overall. Significant variances indicate that participants meaningfully differed in this tendency. Thus, for example, despite the linear slopes being
negative, at least 1 participant had a positive slope where the variance was statistically significant.
*P < .05; **P < .001.
1,2,3
Indicates number of fit indices showing good to excellent fit. When the number is higher, we can be more certain that the model describes the overall sample well. Further information
on fit is available in individual outputs in the Supplementary Data.
a

Variance was fixed to 0 to permit estimation.
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symptom, the intercept would be enough to characterize their
data, while the existence of a slope denotes that there are systematic changes in the symptom. A linear slope indicates a tendency
up or down. A quadratic slope indicates some curve to the line’s
shape. A cubic slope indicates a second curvature of the line. The
modeling allows us to determine whether the data are well characterized by the intercept and 1 or more slopes, as well as how
many slopes are required to characterize the data of participants
overall. The modeling also allows us to determine whether and
how individual participants significantly vary from the average
group trajectory. For example, the model might show that the
mean slope is negative, indicating resolution of a symptom, but
with significant variance, indicating that some participants are
better characterized by an upward slope of symptoms.
Of the symptoms, only nausea was not reasonably well characterized by a latent trajectory model. As shown in Table 1, all
other symptoms were best characterized by at least 1 curvilinear
slope in addition to a linear slope, typically showing a decrease
but with deceleration. Because we only analyzed those participants who reported the symptom at some point, the number for
each model (vs 162 who supplied any EMA) shows how commonly the symptom was reported. The most common symptoms were fatigue, fever, reduced appetite, and problems with
sense of taste. The linear slopes all had negative means. Thus,
participants on average tended to show reductions in symptoms
over time, but the significant variance of most of the slopes indicates that many participants showed increases in symptoms. As
a reminder, there was no indication that participants differed in
these trajectories based on treatment group.
On the average, judging from the linear slope values, participants recovered the quickest from aches and low appetite
and most slowly from cough and difficulty breathing. With the

reported were mostly White (70%, n = 106), although many
participants reported that they were Black (25%, n = 38), with
an average age (SD) of 45.80 (13.04). The sample was primarily
female, as judged by the number reporting being assigned female sex at birth (69%, n = 109).

Appetite

Breath

Chills

Cough

Diarrhea

Fatigue

Fever

Nausea

Smell

Taste

Y-axis of each graph shows symptom severity (0–10);
each row is data from 1 participant

Ache

slowly or were exacerbated. In the latter 2 cases, the 10 participants with the most extreme linear slopes had their parameters averaged to depict a typical rapidly improving and slowly
improving course (with the exception of diarrhea, for which
the most extreme quadratic courses were averaged because the
linear slope had no variance). Finally, the single participant
who deteriorated according to study criteria yet also provided
a full set of EMA data is also presented. This participant experienced moderate deterioration and visited the emergency
room midway through the reporting period. Examining this
participant’s raw data revealed no obvious signs of the deterioration aside from 3 elevated ratings of shortness of breath (a 5 or
6 out of 10) that occurred around this period, with these ratings
surrounded by ratings of 0.
A further depiction of the wide variety of slopes is provided
in Figure 3. Here we depict trajectories for the 5 symptoms with
the best-fitting models. On the left, we see the average course
of all of these symptoms is an improvement in mild symptoms
that slows down. On the right, 9 randomly selected participants

Time points (0-30)
Figure 1. Up to a 17-day course (median, 16) of symptoms for 10 randomly selected participants on a per-symptom basis. Each row includes data for 1 participant. Time
points are ~12 hours apart on up to 17 days. Note the “saw tooth” pattern for many participants, indicating symptoms that wax and wane. An expanded version of this figure
is available in Supplementary Data.
Heterogeneity in COVID-19 • ofid • 5
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exception of problems with sense of taste, all other symptoms
had a second quadratic term that was positive, which indicates
that although their symptoms went down, the rate at which they
dropped began to slow. Thus, the most typical course was an initially rapid recovery followed by some plateauing, or a pattern of
decelerating improvement. Most symptoms had significant variance in both the linear and quadratic slope, which means that
the curve could also move in a different direction for some participants. For example, some participants increased in symptoms
and then decreased, whereas others had stable levels of symptoms
or had increased symptoms that were maintained across the rest
of the reporting period. The picture is even more complicated
for taste, which had an additional cubic slope. This symptom
thus showed at least 2 inflection points for many participants, as
would be true if the symptom went up, down, and then up again.
Figure 2 displays illustrative curves for each symptom. These
figures display the most typical (mean) course, alongside the
typical course of (1) participants whose symptoms reduced rapidly, as well as (2) those whose symptoms either reduced more

Ache
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Breath

Chills

Cough

10.0

7.5

5.0

Symptom severity

Subgroup

0.0

Average

Diarrhea

Fatigue

Fever

Smell

Rapid improvement

Taste

Slower improvement

10.0

Deteriorated

7.5

5.0

2.5

0.0
0

1

2

3

4 0

1

2

3

4 0

1

2

3

4 0

1

2

3

4 0

1

2

3

4

Time
Figure 2. Representative courses of coronavirus disease 2019 symptoms across up to 17 days (median, 16 days). Each time point represents the average of 3 days, except
that Time 4 included up to 5 days, but more typically 3 or 4. The Average line represents the average trajectory across the entire data set. The Rapid improvement and Slower
improvement lines are the average for the 10 participants, with the strongest linear slope in the improving and worsening directions. For diarrhea, the quadratic slope was
used as the linear slope had no variance. A worsening linear slope did not always translate to symptoms being aggravated overall because trajectories were curvilinear.
Slower improvement lines are not depicted for appetite or chills because too few participants experienced worsening in this symptom as indexed by the linear slope. The
Deteriorated lines provide the slope for the single participant who deteriorated midway through the trial yet provided a full set of data.

show us that these average trajectories vary significantly across
individuals, with symptoms rising and falling at different rates
across people. An expanded version of this figure is available in
the Supplementary Data.

time. In contrast, for a participant with fever and trouble
breathing, we would have no reason to expect that a reduction
in fever should necessarily go along with improved breathing,
because the correlation is small and negative.

How Symptoms Change Together Over Time

Symptom Dynamics, Demographics, and Clinical Deterioration

Table 2 shows the correlations among linear slopes. Each
person’s linear slope tells us to what extent their symptoms generally tend to go up or down over time. The correlation between
these slopes tells us whether we should expect that participants
have symptoms that go together as they improve or worsen.
Some pairs stood out with particularly strong correlations.
These include problems with taste and smell, cough and trouble
breathing, chills and fever, and, to a lesser extent, ache and fatigue. Thus, for example, we would expect that for a participant
whose symptoms included both cough and trouble breathing
these symptoms would tend to go up or down together over

Most participants who deteriorated did so in the first several
days and stopped providing EMA data. Thus, most of the 9
participants who deteriorated provided data only for Time
0 for the trajectories presented. Accordingly, we examined
differences between the 9 participants who deteriorated (ie,
developed dyspnea and hypoxia) and the rest of the sample
only in the intercepts (the only meaningful trajectory information for participants who only reported during Time
0). Given the small sample of participants who deteriorated, Mann-Whitney U tests were conducted. Two effects
retained statistical significance above a correction for the
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Figure 3. On the left, the average course of 5 common symptoms across up to 17 days (median number of days, 16). On the right, 9 randomly selected participants (of those
who had all 5 symptoms) and their individual trajectories. Note that because the model fits a curve to data points, the curve can transiently go above the response scale. An
expanded version of this figure is available in the Supplementary Data.

number of tests conducted in this analysis: Participants who
deteriorated were far more likely to have an elevated intercept (ie, higher initial levels) for both cough and diarrhea
(all P = .002).

Table 2.

We also examined demographic variables to see if symptom
dynamics differed, adopting a P of .01 to balance multiple
testing against discovery of potentially important findings. Men
and women showed no differences in any intercepts or slopes.

Partial Correlations Between Pairs of Linear Slopes Controlling for Intercepts With Number of Participants for Each Comparison
Ache

Ache

Appetite

Breath

Chill

Cough

Fatigue

Fever

Smell

Taste

97

75

68

100

114

63

90

93

73

65

100

115

61

89

97

54

82

85

47

68

76

62

72

50

50

61

118

63

93

98

69

104

111

Appetite

0.26*

Breath

0.39**

0.09

Chill

0.33**

–0.01

Cough

0.36**

0.13

**

Fatigue

0.51

0.44

Fever

0.06

0.10

0.38**
**

0.68**

0.23

0.46**

0.31**

0.33**

–0.04

0.65**

**

0.09

0.15

Smell

0.23*

0.30

0.04

0.00

0.18

0.32**

–0.11

52

Taste

0.23*

0.35**

0.07

0.19

0.23*

0.31**

0.09

58
104

0.74**

No. for each comparison is on the top diagonal. Positive correlations indicate that symptoms tend to go either or up or down together. Negative correlations indicate that the symptoms
diverge in trajectories (as 1 goes up, the other goes down). Thus, problems with smell are very likely to resolve along with problems with taste. Diarrhea is not included in these analyses
because its linear slope had a variance of 0, which means it cannot correlate with other slopes.
*P < .05; **P < .01.
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Black participants had a significantly higher intercept of chill
and cough (all P < .007), suggesting more severe symptoms
at the start of the study. No other slopes or intercepts showed
clearly significant differences. Body mass index (BMI) did not
correlate significantly with any intercepts or slopes. Thus, there
were few signs that demographic variables were related to the
course of COVID-19 symptoms.

Our study characterizes the course of COVID-19 among
community-dwelling patients who are recovering at home.
This information is important because it informs clinicians,
patients, and researchers about the high degree of heterogeneity, both between and within patients. We made the following 4 major observations: First, the COVID-19 symptom
course is highly heterogenous. Second, early symptoms related to participant demographics and clinical deterioration.
Third, symptoms often showed a pattern of decelerating improvement. Fourth, some symptoms are likely to improve
in tandem, whereas others are not. We discuss each of these
points further below.
The overall picture is of symptoms reducing for most participants, but often with a slowing of this reduction, often further
complicated by waxing and waning of symptoms (eg, across
12-hour periods). Further, problems with the sense of taste were
characterized by additional curvilinearity, reflecting increased
volatility. As a notable example, the participant who clinically
deteriorated (developed dyspnea and hypoxia) did this in spite
of symptoms showing average or rapidly improving course in
some respects. Although this is a report of only a single participant who experienced moderate deterioration, it stands as
a warning that deterioration in COVID-19 can be rapid and
unpredictable.
We found no evidence that symptom dynamics varied meaningfully across the treatment groups from the parent study, nor
any association with BMI. However, participants who deteriorated were more likely to have initially high levels of cough
and diarrhea. This finding should be taken as exploratory and
requiring confirmatory tests of whether higher levels of these
symptoms in the initial days of illness might presage clinical deterioration, especially because 3 of our deteriorated participants
were deteriorated at baseline. Importantly, our more global
findings indicate that the time frame of assessment might be
crucial. Our finding is that participants with higher self-report
of cough and diarrhea near the beginning of their illness were
more likely to experience deterioration at some point. Because
symptom courses often wax and wane, asking participants if
they ever experienced that symptom or experienced it later in
the illness would not necessarily yield the same result. However,
at least 1 report has found that diarrhea presaged clinical deterioration [18]. We expect that our finding regarding cough
8 • ofid • Rodebaugh et al

Limitations

The results of the study should be interpreted in light of its limitations. Patients were enrolled after diagnosis, which could have
been up to 7 days after experiencing symptoms, and even longer
after infection. This fact could explain some of the wide variety
of trajectories, but not the observed waxing and waning or
stalled improvement. Data were drawn from an RCT, with limited diversity in patient population, conducted in 1 Midwestern
metropolitan area, during the initial 7 months of the COVID19 outbreak. It is unclear to what extent we should expect prevalent symptoms of COVID-19 or their course to vary by virus
variant, demographics, community, or even country. It is possible that although asking participants first whether they had a
symptom or not may have reduced patient burden, it may also
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DISCUSSION

might simply reflect the fact that most of those who deteriorated did so early in the reporting period, but the possibility that
severity of cough actually predicts deterioration seems worth
investigating.
Our findings indicate that patients and health care providers
can expect a variety of symptom courses, including the development of additional symptoms and a gradual and potentially
stalling decline of some symptoms. The latter finding is consistent with another study showing that a minority of participants continue to experience symptoms, particularly cough,
fatigue, and shortness of breath [6]. In our results, cough and
shortness of breath showed the smallest slope downward on
average, suggesting, in combination with previous results, that
these symptoms in particular are likely to be prolonged for
many patients.
Whether the decelerating improvement pattern is unique
to COVID-19 is difficult to determine because few studies
have examined other common infectious diseases in regard to
common trajectories of symptoms. However, a report focusing
on the development of a symptom measure for influenza reported the average course of several symptoms [19]. Although
challenging to compare directly due to differences in methodology, our results seem to suggest (1) a longer course for significant symptoms of COVID-19 and (2) a greater deceleration
in improvement across the second week. That is, for influenza
symptoms, rapid recovery over the first 4 days (Time 0 to Time 1
in our analysis) was followed by a more gradual, approximately
linear slope for the remainder of the days assessed. Our participants experienced more gradual initial improvement, followed,
most commonly, by a greater deceleration of improvement.
Judging from correlated slopes, some pairs of symptoms are
likely to reduce in tandem. The strongest candidate for such a
pairing is problems with smell and taste, which should be expected given the functional connection between the 2 senses.
Similarly, cough and shortness of breath, fever and chills, and,
to a lesser extent, ache and fatigue are all pairs that show a tendency to decline over time together.

CONCLUSIONS

In conclusion, COVID-19 is a heterogeneous illness in terms
of subjective symptoms and course. When patients experience
a given symptom, it may fluctuate but will typically follow a
gradual improvement over the course of 2 weeks or more. Many
patients, however, will develop new symptoms during the same
course, and many symptoms may take considerably beyond a
2-week window to resolve completely. This tendency toward
slowly improving symptoms may be related to the increasing
reports of a more chronic form of the disease in certain populations [6, 8, 11]. It is important to warn patients, and clinicians
caring for them, not to expect a linear decrease in all symptoms;
some may be intermittent or get worse before they get better.
Future studies following a cohort of patients with COVID-19
symptoms over a longer period of time could be useful in determining how, if at all, acute symptom presentation relates to
chronic symptom experiences.
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have inclined participants to answer “no” even if a symptom
was present in a mild form. Participants provided self-report
of symptoms, which especially must be kept in mind when attempting to apply results to objective conditions. For example,
1 report found that a significant proportion of participants with
COVID-19 reporting olfactory dysfunction did not meet criteria upon evaluation [20]. Nevertheless, self-reported symptoms of problems with smell and taste have emerged as 2 of the
best predictors of COVID-19 status [21, 22].

